基本情况
姓名：庞冀燕

性别：女

出生年月：1973-12

籍贯：暂无资料

职位：副教授,博士生导师

联系方式

邮箱：cespjy@mail.sysu.edu.cn

通讯地址：广东省广州市中山大学化学学院

邮编：510275

个人网站：暂无资料

教育经历
1991.9 - 1995.6 沈阳药学院 获学士学位 
1995.9 - 1998.6 沈阳药科大学 获硕士学位 
2000.9 - 2003.6 中山大学 获博士学位

工作经历
1998.8 - 2000.8   广东省汕头市鮀滨制药总厂，职员 
2003.7 - 2006.12 中山大学化学与化学工程学院，讲师 
2004.7 - 2004.11 香港浸会大学中医药学院，研究访问学者 
2007.1 -     现在   中山大学化学学院，副教授

讲授课程
基础有机化学实验、有机化学、药物化学与药物设计

科研方向
（1）致力于靶向降解剂技术的研究与开发，着重在针对神经退行性疾病和抗肿瘤降解剂的设计、合成和分子机制及新药开发方面开展工作；（2）致力于海洋天然产物和中药的发现、结构修饰、构效关系及应用基础研究，着重在海洋微生物来源的新型防治心脑血管、神经退行性疾病、抗肿瘤，以及抗病毒候选药物的发现，构效关系，作用机制研究及新药开发方面开展工作。

代表性科研项目
1）国家自然科学基金面上项目, 靶向α-Syn/tau聚集体双效降解剂的设计、合成及在神经退行性病变的研究， 批准号：22477149，主持人。2025.01- 2028.12
2）国家自然科学基金面上项目, 海洋真菌中Xyloketal衍生物的合成及对动脉粥样硬化发病氧化应激信号通路中NADPH氧化酶的抑制和分子机制探讨, 批准号：21172271，主持人，2012.01- 2015.12.12。
3）广东省自然科学基金重点项目，Xyloketals化合物对氧化应激通路中NADPH氧化酶的抑制及分子机制，批准号：S2011020001231，主持人。2011.10- 2014.10。
4）科技部重大专项 “重大新药创制”， 来自海洋真菌的防治心脑血管疾病候选药物Xyloketal B的研究,第一副组长。批准号：2009ZX09103-039，2009.1-2010.12。
5）国家自然科学基金青年项目，海洋真菌中结构珍奇的新型钙通道阻滞剂Xyloketals衍生物的制备及构效关系，批准号：20802094，主持人。2009.1-2011．12。

主要论著
1、Wenzhang Xiong, Wentao Zhu, Jiyan Pang *, Wenbo Liu *. Rapid amide ligation between α-haloacylsilanes and amines under aqueous conditions. Nat. Comm. 2025, Online. https://doi.org/10.1038/s41467-025-65617-y.
2、Wentao Zhu, Wenqian Zhang, Yinmiao Wang, Jian Chen, Fang Xu, and Jiyan Pang *. Modular Assembled Targeting Chimera Enables Multimodal Targeted Protein Degradation. JACS Au. 2025 , 5, 5635−5647.
3、Wentao Zhu, Jian Chen, Wenqian Zhang, Yinmiao Wang, Fang Xu, and Jiyan Pang  *.  Discovery of the First Potent PI3K/mTOR Dual-Targeting PROTAC 
Degrader for Efficient Modulation of the PI3K/AKT/mTOR Pathway. J. Med. Chem. 2025, Online. https://doi.org/10.1021/acs.jmedchem.5c02244.
4、Wentao Zhu, Wenqian Zhang, Jian Chen, Yichen Tong, Fang Xu, and Jiyan Pang *。Discovery of Effective Dual PROTAC Degraders for Neurodegenerative Disease-Associated Aggregates. J. Med. Chem. 2024, 67, 3448−3466
5、Jian Chen, Wentao Zhu, Wenqian Zhang, Yichen Tong, Fang Xu, and Jiyan Pang *. Discovery of the First Potent DYRK2 Proteolysis Targeting Chimera Degraders. ACS Medicinal. Chem. Lett. 2024, 15, 659-666.
6、Yichen Tong, Wentao Zhu, Jian Chen, Wenqian Zhang, Fang Xu * and Jiyan Pang *. Targeted Degradation of Alpha-Synuclein by AutophagosomeAnchoring Chimera Peptides. J. Med. Chem. 2023, 66,12614-12628.
7、Yichen Tong, Wentao Zhu, Jian Chen, Tianzhi Wen, Fang Xu and Jiyan Pang *. Discovery of Small-Molecule Degraders for Alpha-Synuclein Aggregates. J. Med. Chem. 2023, 66, 7926-7942.
8、Tianzhi Wen, Jian Chen, Wenqian Zhang and Jiyan Pang *. Design, Synthesis and Biological Evaluation of α-Synuclein Proteolysis-Targeting Chimeras. Molecules. 2023, 28, 4458
9、Yichen Tong, Wentao Zhu, Yinglin Zheng, Tianzhi Wen, Zere Mukhamejanova, Fang Xu,* Qi Xiang and Jiyan Pang *. Xyloketal B Reverses Nutritional Hepatic Steatosis, Steatohepatitis, and Liver Fibrosis through Activation of the PPARα/PGC1α Signaling Pathway, Journal of Natural Products. 2022, 85, 1738-1750.
10、Wentao Zhu, Yichen Tong, Qianyi Feng, Fang Xu * and Jiyan Pang *. Discovery of Novel Polycyclic Phloroglucinols via an Improved OnePot Method. ACS Omega. 2022, 7, 47174-47182.
11、Yichen Tong, Zere Mukhamejanova, Yinglin Zheng, Tianzhi Wen, Fang Xu * and Jiyan Pang *. Marine-Derived Xyloketal Compound Ameliorates MPP+ Induced Neuronal Injury through Regulating of the IRE1/XBP1 Signaling Pathway, ACS Chemical Neuroscience. 2021, 12, 3101-3111
12、Zere Mukhamejanova, Yichen Tong, Qi Xiang, Fang Xu * and Jiyan Pang *. Recent Advances in the Design and Development of Anticancer Molecules Based on PROTAC Technology. Current Medicinal Chemistry. 2020, 27, 1-24.
13、Yinglin Zheng, Yichen Tong, Xinfeng Wang, Jiebin Zhou and Jiyan Pang *. Synthesis of Marine Peptide Analogues and Their Ability to Promote Proliferation in HUVECs and Zebrafish. Molecules. 2019, 24, 66.
14、Fengyin Liang, Fengjuan Su,Xiaoxiao Wang, Simei Long,Yinglin Zheng,Xiaofei He, Jiyan Pang *, Zhong Pei *. Xyloketal derivative C53N protects against mild traumatic brain injury in mice. Drug Design, Development and Therapy. 2019, 13 173–182.
15、Zhou Jie-Bin, Zheng Ying-Lin, Zeng Yi-Xuan, Wang Jia-Wei, Pei Zhong *, Pang Ji-Yan*. Marine derived xyloketal derivatives exhibit anti-stress and anti-ageing effects through HSF pathway in Caenorhabditis elegans. Eur. J. Med. Chem. 2018, 148, 63-72. 
16、Wang, Pei-yu; Zeng, Wen-jun; Liu, Jie; Wu,Yun-Long; Ma, Yinghui; Zeng, Zhiping; Pang, Ji-yan*;Zhang, Xiao-kun; Yan, Xiaomei; Wong, Alice Sze Tsai; Zeng, Jin-Zhang*. Biochemical Pharmacology, 2017, 124, 19-28. 
17、Zhang Youying, Meng Tian, Zuo Ling, Bei Yu, Zhang Qihao, Su Zhijian, Huang Yadong, Pang Jiyan*, Xiang Qi * and Yang Hongtu. Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models. Marine Drugs. 2017, 15, 163-176.
18、Zhou Jie-Bin, Luo Rong, Zheng Ying-Lin and Pang Ji-Yan *. Recent Advances in the Discovery and Development of Marine Natural Products with Cardiovascular Pharmacological Effects. Mini-Reviews in Medicinal Chemistry, 2018, 18, online. DOI: 10.2174/1389557517666170927112621. 
19、Zhou Jie-Bin, Sun Ying-Ying, Zheng Ying-Lin, Yu Chu-Qin, Lin Hua-Qing *, Pang Ji-Yan *. A study on blocking store-operated Ca2+ entry in pulmonary arterial smooth muscle cells with xyloketals from marine fungi. Acta Pharm. 2017, 67, 557–567.
20、Zeng, Y.; Guo, W.; Xu, G.; Wang, Q.; Long, S.; Liang, F.; Huang, Y.;Li, X.; Li, S.; Zhou, J.; Burgunder, J.; Pang, J. *; Pei, Z. * Design, Development and Therapy. 2016, 10 1443-1451.
21、Liu, S. ; Luo, R. ; Xiang, Q.; Xu, X.; Qiu, L.; Pang, J.* Marine Drugs. 2015, 13: 948-973.
22、Li, Jing; Lu, Xilin; Wu, Qi; Yu, Guangchuang; Xu, Zhongliang; Qiu, Liqin; Pei, Zhong; Lin, Yongcheng ; Pang, Jiyan*. Curr. Med. Chem. 2013, 20, 1183-1194. 
23、Deng, Chun-Mei; Liu, Shi-Xin; Huang, Cai-Huan; Pang, Ji-Yan*; and Lin, Yong-Cheng*. Marine Drug. 2013, 11, 2616-2624. 
24、Li, Shichang; Shen, Cunzhou; Guo, Wenyuan; Zhang, Xuefei; Liu, Shixin; Liang, Fengyin; Xu, Zhongliang; Pei, Zhong; Song, Huacan*; Qiu, Liqin; Lin, Yongcheng; Pang, Jiyan*. Marine Drug. 2013, 11, 5159-89
25、Long, Si-Mei Long; Liang, Feng-Yin; Wu, Qi; Lu, Xi-Lin; Yao, Xiao-Li; Li, Shi-Chang; Li, J ing; Su, Huanxing; Pang, Ji-Yan * and Pei Zhong *. Marine Drug. 2013, 11, 5159-89 
26、Deng, Chun-Mei; Huang, Cai-Huan; Wu, Qili; Pang, Ji-Yan* and Lin, Yong-Cheng*. Nat. Prod. Res. 2013, 27, 1882-1887.
27、Xu, Zhongliang;  Lu, Bingtai; Xiang, Qi; Li, Yiying; Li, Shichang; Lin, Yongcheng; Pang, Jiyan*. Acta Pharmaceutica Sinica B. 2013, 3, 322-327. 
28、Lu, Xi-Lin, Xu, Zhong-Liang, Yao, Xiao-Li, Su, Feng-Juan, Ye, Cheng-Hui, Li, Jing, Lin, Yong-Cheng, Wang, Guang-Lei, Zeng, Jin-Sheng, Huang, Ru-Xun, Ou, Jing-Song, Sun, Hong-Shuo, Wang, Li-Ping, Pang, Ji-Yan* and Pei, Zhong*. Mar. Drugs, 2012, 10, 1307-1320.
29、Zhang, Wei; Liu, Yan; Yang, Hongtu; Li, Zongyi; Huang, Yadong; Xu, Zhongliang; Lin, Yongcheng; Xiang, Qi*; Pang, Jiyan*. J. Chromatogr. B. 2012, 885-886。
30、Li, Jing; Zhang, Dingmei; Zhu, Xun; He, Zhenjian; Liu, Shu; Li, Mengfeng *; Pang, Jiyan*, Lin, Yongcheng*. Marine Drug. 2011, 9, 1887-1901.
31、Xu, Zhongliang; Li,Yiying; Xiang, Qi; Pei, Zhong; Lu, Xilin; Chen, Ling; Wang, Guanlei; Lu, Bingtai; Pang, Jiyan*; Lin,Yongcheng*. J. Med. Chem., 2010, 53, 4642 - 4653. 

相关成果
1、庞冀燕, 温天志。一类靶向α-突触核蛋白的蛋白水解嵌合体及其应用。中国发明专利，授权日：2023年12月15日。专利号：ZL 2022 1 1130925.9。

2、庞冀燕，佟奕辰，一种姜黄素双功能分子及其制备方法和应用，中国发明专利，授权日：2022年11月2日，专利号: ZL201911214677.4.

3、庞冀燕，佟奕辰，林焕怀。一类α-突触核蛋白靶向化合物及其制备方法和应用。中国发明专利，授权日：2023年5月30日。专利号：ZL 2022 1 0159074.4

4、庞冀燕, 郑颖琳，海洋肽类化合物及其制备方法与应用，中国发明专利，授权日：2022年10月18日，专利号：ZL201811280501.4

5、杜艳华，庞冀燕，王冠蕾。海洋微生物来源化合物P-3在制备抗衰老药物中的应用。中国发明专利，授权日：2019年4月19日。专利号：ZL201610281054.9。

6、庞冀燕，林永成，刘诗欣，鲁立，顾振东，兰红军，任洪发，李艺英，王海波，欧雅莉，中国专利，申请日：2014年4月2日，申请号：201410130657.X。专利号： ZL 2014 1 0130657.X；授权公告日：2016, 09,07。（已授权）
7、庞冀燕，裴中，李静，林永成，卢锡林。中国专利，申请号：201210188053.1，申请日：2012年06月18日，专利号： ZL 2012 1 0188053.1；授权公告日：2014, 06, 11。（已授权）
8、裴中，庞冀燕，李世昌，林永成，张雪飞，刘诗欣。xyloketals类似物及其制备方法和应用。中国专利，申请号：201210181451.0；申请日：2012年06月04日。专利号：ZL 201210181451.0；授权日：2014年03月25日。（已授权）
9、 庞冀燕，林永成，许忠良，李艺英，卢秉泰， Xyloketals类化合物的合成方法，中国专利，200910213964.3 申请日：2009.12.18。专利号： ZL 2009 1 0213964, 3；授权公告日：2012, 06, 06. （已授权）
10、 庞冀燕，林永成，许忠良，李艺英，裴中，王冠蕾 。苯并吡喃并呋喃化合物及其制备方法与应用。中国专利，200910213965.8 申请日：2009.12.18。专利号： ZL 2009 1 0213965,8，授权公告日：2012, 02, 29. （已授权）